GSK, Pfizer And Shionogi Owned ViiV Healthcare Announced 12-month Findings From The Solar Phase 3B Head-to-head Study Of Long Acting Cabenuva Regime (CAB+RPV LA) Compared Against Gilead’s Biktarvy Regime (BIC/FTC/TAF)
Study findings showed that CAB+RPV LA dosed every two months achieved the primary endpoint of non-inferior virologic efficacy versus daily oral BIC/FTC/TAF, while 90% of participants who switched to CAB+RPV